CC-99282 is named as a drug or biological intervention in 3 clinical trials in our USA, China and UK trial registers, none of which are currently recruiting. Lead sponsors include Celgene (2) and Genmab (1). Registered phases: Phase 1/2, Phase 1 and Phase 2. Conditions studied include Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Non-Hodgkin Lymphoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05283720 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (ClinicalTrials.gov ↗) Non-Hodgkin Lymphoma |
Phase 2 | Active, closed |
| NCT03930953 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) Lymphoma, Non-Hodgkin |
Phase 1/2 | Active, closed |
| NCT04884035 | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma (ClinicalTrials.gov ↗) Lymphoma, B-Cell |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Lymphoma, Non-Hodgkin | 1 |
| Lymphoma, B-Cell | 1 |
| Non-Hodgkin Lymphoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Celgene | 2 |
| Genmab | 1 |
| Register | CC-99282 trials |
|---|---|
| Clinical trials in USA | 3 |
| Clinical trials in China | 2 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CC-99282 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CC-99282 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.